Advertisement

Toxicology of Sulfonylureas

  • F. Hartig
  • K. H. Langer
  • W. Rebel
  • F. H. Schmidt
  • E. Schütz
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 119)

Abstract

Since 1958, Hoechst AG, Frankfurt, and Boehringer Mannheim GmbH have synthesized and pharmacologically tested a large number of sulfonylurea analogues which elicit hypoglycemic activity in the milligram range and in some cases at less than 0.1mg/kg body weight. Glibenclamide (HB419) was chosen from a group of the most potent compounds for joint research in 1964 and introduced onto the market as Daonil by Hoechst and as Euglucon by Boehringer (Hebold et al. 1969a, b; Mitsukami et al. 1969).

Keywords

Positive Inotropic Effect Canine Femoral Artery TPase Activity Isolate Tissue Preparation Sister Chromatid Exchange Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achelis JD, Hardebeck K (1955) Über eine neue blutzuckersenkende Substanz. Dtsch Med Wochenschr 80:1452–1455PubMedCrossRefGoogle Scholar
  2. Ambrogi V, Bloch K, Daturi S, Griggi P, Logemann W, Mandelli V, Parenti MA, Rabini T, Usardi MM, Tommasini R (1971) Pharmacological study on a new oral antidiabetic: N-4-beta-(5-methylpryrazine-2-carboxamido)ethylebenzenesul-fonyl-n’-cyclohexylurea or K4024. Arzneimittelforschung 21(2):208–215.Google Scholar
  3. Baeder C, Sakaguchi T (1969) Teratologische Untersuchungen mit HB 419, Arzneimittel Forsch 1419–1420Google Scholar
  4. Bänder A (1971) Zur Pharmakologie und Toxikologie der blutzuckersenkenden Sulfonamide. Handbuch der experimentellen Pharmakologie. Springer, Berlin Heidelberg New York, pp 318–401Google Scholar
  5. Ballagi-Pordány G, Koltai M-Z, Aranyi Z, Pogátsa G (1990) Direct cardiovascular effect of hypoglycemic sulphonylurea compounds. Diabetologia 33 [Suppl]:A53Google Scholar
  6. Brown JD, Brown ME (1977) The effect of tolbutamide on contractility and cyclic adenosine 3’:5’-monophosphate concentration in the intact beating rat heart. J Pharmacol Exp Ther 200:166–173PubMedGoogle Scholar
  7. Curtis GP, Setchfield J, Lucchesi BR (1975) The cardiac pharmacology of tolbutamide. J Pharmacol Exp Ther 194:264–273PubMedGoogle Scholar
  8. Duhault J, Boulanger M, Tisserand F, Beregi L (1972) The pharmacology of S 1072, a new highly effective oral antidiabetic drug with unusual properties. Arzneimittelforschung (Drug Res) 22:1682–1685Google Scholar
  9. Dulin WE, Oster HL, McMahon FG (1961) A new high potency antidiabetic sulfonylurea [n-(l-hexahydro-l-azepinyl)-N’-p-tolylsulfonylurea]. Proc Soc Exp Biol 107:245–248PubMedCrossRefGoogle Scholar
  10. Findlay I (1992) Effects of pH upon the inhibition by suphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle. J Pharmacol Exp Ther 262:71–79PubMedGoogle Scholar
  11. Heboid G (1971) Experimentelle, geschlechtsdifferente Beeinflussung der Langer-hans’schen Inseln des Pankreas. Habilitationsschrift, University of HeidelbergGoogle Scholar
  12. Heboid G, Scholz J, Schütz E, Czerwek H, Sagagushi T, Brunk R, Notdurft H, Kief H, Bäder C, Hartig F (1969a) Experimental investigations of the new sulfonylurea-derivate glibenclamide Hb 419. Horm Metab Res 1:4–10Google Scholar
  13. Heboid G, Scholz J, Schütz E, Czerwek H, Brunk R (1969b) Verträglichkeitsprüfungen von Hb 419 im Tierversuch. Arzneimittelforschung 19:1404–1413Google Scholar
  14. Herman EH, Krop S, Jordan W (1982) Tolbutamide enhancement of ouabain cardiotoxicity in rabbits. Pharmacology 24:111–117PubMedCrossRefGoogle Scholar
  15. Hoffmann-La Roche (1985) Basic documentation on Glutril. Hoffmann-La Roche, Basel, pp 1–15Google Scholar
  16. Iida H, Kast A, Tsunenari Y (1976) Studies on the teratogenicity of a new sulfonylurea derivative (ARDF 26 SE) in rats and rabbits. Pharmocometrics 11:119–131Google Scholar
  17. Kast A, Tsunenari Y, Honma M, Nishikawa J, Shibata T, Torii M (1975) Toxico-logical tests of a new sulfonylurea derivate (ARDF 26 SE) in rats, mice and rabbits. Pharmacometrics 10:383–394Google Scholar
  18. Kiso To Rinsho (1972) Clinical report (Yubunsh Co). 6:1925Google Scholar
  19. Kleiss D, Rech M (1977) Langzeituntersuchungen an alloxandiabetischen Kaninchen — Stoff-wechselverhalten, Allgemeinbefinden, Kreislaufuntersuchungen und Organbefunde — unter chronischer Gabe von Tolbutamid und Methoxy-Methyl-Indolcarbonsäure. Dissertation, University of HeidelbergGoogle Scholar
  20. Krall LP (1984) Glyburide (DiaBeta®): a new second generation hypoglycemic agent. Clin Ther 6(6):746–762PubMedGoogle Scholar
  21. Kramer JH, Lampson WG, Schaffer SW (1983) Effect of tolbutamide on myocadial anergy metabolism. Ann J Physiol 245:H313–H319Google Scholar
  22. Kramer M, Hecht G, Lanecker H, Harwart A, Richter KD, Gloxhuber C (1964) Pharmako-logie des 2-Benzolsulfonamido-5(β- methoxy-äthoxy)-pyrimidins (Glycodiazin), einer neuen blutzuckersenkenden Verbindung. Arzneimittelforschung 14:377–385PubMedGoogle Scholar
  23. Lampson WG, Kramer JH, Schaffer SW (1985) Effect of tolbutamide on myocardial energy metabolism of the ischemic heart. Biochem Pharmacol 34:803–809PubMedCrossRefGoogle Scholar
  24. Lebovitz HE, Melander A (1992) Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds) International textbook of diabetes mellitus. Wiley, New YorkGoogle Scholar
  25. Lee KC, Wilson RA, Randall DC, Altiere RJ, Kiritsy-Ray JA (1988) An analysis of the haemodynamic effects of tolbutamide in conscious dogs. Clin Exp Pharmacol Physiol 15:379–390PubMedCrossRefGoogle Scholar
  26. Lorch E, Gey KF, Sommer P (1972) Glibornurid, ein neues hochwirksames Antidiabetikum Pharmakologische und biochemische Vergleichsuntersuchungen an verschiedenen Tierspezies und an tierexperimentellen Modellen. Arzneimittelforschung (Drug Res) 22(12a):2154–2163Google Scholar
  27. Maha GE, Kirtley WR, Root MA, Anderson RC (1962) Acetohexamide, preliminary report on a new oral hypoglycemic agent. Diabetes 11:83–90PubMedGoogle Scholar
  28. McKean, Branz AJ (1992) Influence of ATP-sensitive potassium channel blocker on hypoxia-induced damage of isolated guinea pig heart. Gen Pharmacol 23: 921–923PubMedCrossRefGoogle Scholar
  29. Mitsukami K, Myamoto M, Hayashi S, Kobayashi T, Sukurai M, Sakagushi T (1969) Toxikologische Untersuchungen von N-4-[2-(5-cholor-2-methoxy-benzamido)-acetyl]phenylsulfonyl-N-cyclohexylharnstoff (Hb 419). Arzneimittelforschung 19:1413–1419Google Scholar
  30. NCI report (1977a) Bioassay of acetohexamide for possible carcinogenicity (CAS no 968 81–0)Google Scholar
  31. NCI report (1977b) Bioassay of tolazamide for possible carcinogenicity (CAS no 1156–19-0)Google Scholar
  32. NCI Carcinogenesis Bioassay (1978) Chlorpropamide (NCITR* NCI-CG-TR-45,78); tolbutamide (NCITR* NCI-CG-TR-31,77)Google Scholar
  33. Pfeiffer EF (1984) Are the “second generation” oral hypoglycemic agents really different. Acta Diabetol Lat 21(l):l-32Google Scholar
  34. Renner HW, Münzinger R (1980) Mutagenicity of sulphonylureas. Mutat Res 77: 349–355PubMedCrossRefGoogle Scholar
  35. Schad H, Heimisch W, Maier-Rudolph W, Mendier M (1993) Effect of glibenclamide on myocardial blood flow and function. Eur J Physiol 422 [Suppl 1]:R111Google Scholar
  36. Schaffer SW, Poole CG, Lampson WG, Kramer JH (1981) Effect of tolbutamide on the mechanical function of the isolated rat heart subjected to global ischemia. J Mol Cell Cardiol 13:341–345PubMedCrossRefGoogle Scholar
  37. Schärer K, Hummler H (1971) Toxicological experiments with drugs of the sulfonylurea type in animals. In: Dubach UC, Bückert A (eds) Recent hypoglycemic sulfonylureas, mechanisms of action and clinical indications. Huber, Bern, pp 163–170Google Scholar
  38. Schneider JA, Salgado ED, Jäger D, Delahunt C (1959) The pharmacology of chlorpropamide. Ann N Y Acad Sci 74:427–442PubMedCrossRefGoogle Scholar
  39. Scholz J, Bänder A (1956) Über die orale Behandlung des Diabetes mellitus mit N-[4-Methylbenzolsulfonyl]-N′-butylharnstoff (D860), Pharmakologie. Dtsch Med Wochenschr 81:825–826Google Scholar
  40. Tan BH, Wilson GL, Schaffer SW (1984) Effect of tolbutamide on myocardial metabolism and mechanical performance of the diabetic rat. Diabetes 33: 1138–1143PubMedCrossRefGoogle Scholar
  41. Tettenborn D (1974) Zur Toxikologie von Glisoxepid, einem neuen oralen Antidiabetikum. Ergebnisse der Tieversuche. Arzneimittelforschung (Drug Res) 24:409–418Google Scholar
  42. University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset. Diabetes 19 [Suppl II]:789–830Google Scholar
  43. Wales JK, Grant AM, Wolff FW (1971) The effect of tolbutamide on blood pressure. J Pharmacol Exp Ther 178:130–140PubMedGoogle Scholar
  44. Warnik PR, Davis FB, Davis PJ, Mylotte KM, Blas SD (1986) Differential activities of tolbutamide, tolazamide, and glyburide in vitro on rabbit myocardial membrane Ca2+-transporting ATPase activity. Diabetes 35:1044–1048CrossRefGoogle Scholar
  45. Watson WAF, Petrie JC, Galloway DB, Bullock I, Gilbert JC (1976) In vivo cytogenetic activity of sulphonylurea drugs in man. Mutat Res 38:71–80PubMedCrossRefGoogle Scholar
  46. Wu CF, Haider B, Ahmed SS, Oldewurtel HA, Lyons MM, Regan TJ (1977) The effects of tolbutamide on the myocardium in experimental diabetes. Circulation 55:200–205PubMedCrossRefGoogle Scholar
  47. Yasuba M, Matsuoka N, Iida M, Maeda K, Nishiwaki T, Ueda N, Ohnishi K, Tatsumi H, Hashimoto M (1981). Acute, subacute, and long-term toxicity studies of gliclazide in diabetic animals. Yakuri To Chiryo 9(ll):4497–4520Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • F. Hartig
  • K. H. Langer
  • W. Rebel
  • F. H. Schmidt
  • E. Schütz

There are no affiliations available

Personalised recommendations